Talazoparib and enzalutamide tied to improved overall survival in metastatic prostate cancer
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
HealthDay on MSN2d
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate Cancer
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination r ...
ascopubs.org4d
Patient characteristics and survival in primary prostate sarcomas: An analysis of the SEER database.
Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 ...
Medscape3d
Medscape Pharmacist News
GUCS 2025 Talazoparib Combo Prolongs Survival in Mets Prostate Cancer Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic castration ...
pharmaphorum1d
PARP rivals close in on AZ and Merck's market leading Lynparza
Today, Pfizer said that its phase 3 TALAPRO 2 trial of PARP drug Talzenna (talazoparib) in combination with its Astellas-partnered anti-androgen therapy Xtandi (enzalutamide) reduced radiographic ...
pharmaphorum6d
J&J gets restricted label for PARP drug Akeega in EU
Analysts think a stronger challenge to Lynparza in first-line mCRPC could come from another PARP drug, Pfizer’s Talzenna (talazoparib) combined with Xtandi (enzalutamide), which reported new ...